Evidence map›Paper›PMID 28085956›Full record

SynthesisPloS one2017

MiRNAs Predict the Prognosis of Patients with Triple Negative Breast Cancer: A Meta-Analysis.

Yanli Liu, Yuchao Zhang, Qingfu Li, Junfang Li, Xiaotian Ma, Jinfang Xing, Shouhua Rong, Zhong Wu, Yuan Tian, Jing Li and 1 more

Expression of concernOpen access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. MicroRNAs in regulation of triple-negative breast cancer progression.Journal of cancer research and clinical oncology · 2018
    Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yanli LiuDepartment of Reproductive Center, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Yuchao ZhangDepartment of Clinical Laboratory, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Qingfu LiDepartment of Stomatology, the People's Hospital of Henan Province, Zhengzhou, People's Republic of China.
Junfang LiDepartment of Clinical Laboratory, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Xiaotian MaDepartment of Clinical Laboratory, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Jinfang XingDepartment of Clinical Laboratory, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Shouhua RongDepartment of Clinical Laboratory, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Zhong WuDepartment of Clinical Laboratory, Women and Infants Hospital of Zhengzhou Affiliated to Henan University, Zhengzhou, People's Republic of China.
Yuan TianDepartment of Clinical Laboratory, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Jing LiDepartment of Clinical Laboratory, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Liting JiaDepartment of Clinical Laboratory, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Third Affiliated Hospital of Zhengzhou University · CNZhengzhou People's Hospital · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposemiRNAs are stable and can be extracted from tissues, blood and other body fluid without degradation. miRNAs are abnormally expressed in the presence of a pathological status, including cancer. Therefore, miRNAs are ideal biomarkers for cancer diagnosis and prognosis. Patients with triple negative breast cancer (TNBC) suffer the worst prognosis, although great efforts have been made. Many studies have investigated the role of miRNAs in predicting the outcomes of TNBC patients for better adjustment of treatment. However, results were inconsistent. Thus, we performed a meta-analysis to summarize the published studies for conclusive results.

methodsEligible studies from different database were retrieved from the online databases, and we used STSTA 12.0 to analysis the prognostic role of miRNAs in triple negative breast cancer.

resultsOverall high miRNA expression indicated a worse survival with HR value of 1.78 (95% CI: 0.97-3.25). However, subtotal HRs of oncogenic miRNAs and tumor suppressive miRNAs were 2.73 (95% CI: 2.08-3.57; P<0.001) and 0.44 (95% CI: 0.21-0.90; P = 0.024), respectively, and no heterogeneity was observed within the subgroups.

conclusionsThe miRNAs showed a slightly stronger prognostic value for disease-free survival, relapse-free survival and distant metastasis-free survival compared to the overall survival of TNBC patients. Circulating miRNAs could serve as potential biomarkers for the prognosis of TNBC patients and need further investigation.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorFemaleHumansMicroRNAsPrognosisTriple Negative Breast NeoplasmsBiomarkers, TumorMicroRNAs

Identifiers

PMID28085956
PMCPMC5234799
OpenAlexW2571630699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.